Clinical effects and pharmacokinetic variables of romifidine and the peripheral α2 -adrenoceptor antagonist MK-467 in horses.

The research article explores how the combination of romifidine and MK-467 can maintain sedation quality in horses while also preventing undesirable cardiovascular changes commonly associated with the use of romifidine alone. The work established that when both drugs are administered intravenously, they safely attenuate the cardiovascular effects of romifidine.

Study Design and Methods

• The study used an experimental, randomized, crossover design approach and engaged seven healthy horses (mares) as the test subjects.
• The drugs, romifidine (R) and MK-467 (MK), were administered alone and in combination (R+MK) through intravenous (IV) injection.
• Various factors such as sedation and borborygmi (intestinal activity) were scored. Measurements for heart rate (HR), arterial blood pressure (ABP), respiratory rate, and venous plasma drug concentrations were taken.
• Arterial and venous blood gas analyses were performed and pharmacokinetic parameters were calculated.
• Data was statistically analyzed using linear mixed models for repeated measures, and one-way anova for repeated measures with Bonferroni multiple comparison tests, paired Student’s t-tests.

Results and Findings

• The administration of romifidine alone led to an increase in arterial blood pressure, and a decrease in heart rate and respiratory rate.
• The combination therapy (R+MK) lowered heart rate, respiratory rate, systolic and mean arterial blood pressure.
• MK-467 when administered alone caused increases in both heart rate and respiratory rate.
• The arterial blood pressure after R administration was significantly higher than after the combination (R+MK), suggesting the combination can help control hypertension linked with romifidine use.
• Intestinal activity decreased significantly after R administration whilst there was a less marked decrease after the combined therapy.
• Important pharmacokinetic variations were noted. The combined treatment increased the volume of distribution and the clearance of romifidine and lowered the area under the concentration time curve extrapolated to infinity.

Conclusion

• Intravenously administered romifidine and MK-467 together preserved the sedation quality in horses while also preventing the cardiovascular changes often seen with romifidine use.
• This combined therapy can be beneficial in conditions that require minimizing the cardiovascular effects of romifidine such as in horses with colic or those undergoing general anesthesia.